Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome…

By R. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H. Escobar-Morreale, W. Futterweit, R. Lobo, R. Norman, E. Talbott, D. Dumesic. Journal of Clinical Endocrinology and Metabolism, 2010

970 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/5556ce96457d5a9ef1f00894a9f61047e5c6afb4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Reproductive Medicine

1. H. Escobar-Morreale
2. E. Diamanti-Kandarakis
3. D. Dumesic
4. Didier Dewailly
5. R. Azziz

Citations in the corpus

• Polycystic ovary syndrome: etiology, pathogenesis and diagnosis (2011, background): “Statins, competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that diminish cholesterol synthesis and decrease circulating LDL cholesterol levels, can be added if dyslipidemia or other risk factors persist”
• The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. (2014, background): “According to the AE-PCOS Society, an oral glucose tolerance test should be performed in all obese women, as well as in lean PCOS women with advanced age ( O 40 years), in the presence of a personal history of gestational diabetes or family history of T2D (80, 81).”